our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BGB-108

News alerts, weekly reports and conference planners

Company:

BeiGene

Drug class:

PD1 inhibitor

Related drugs:

‹

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab-jsgr (84)

dostarlimab-gxly (43)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

MGD013 (5)

nivolumab/relatlimab-rmbw (4)

geptanolimab (3)

iparomlimab/tuvonralimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

ONCR-177 (0)

OSE-279 (0)

PD-1-KO-T cell injection (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

›

almost2years

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov)

P3, N=650, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

almost 2 years ago

New P3 trial • Combination therapy • Metastases

PD-L1 (Programmed death ligand 1)

carboplatin • Qibeian (iparomlimab/tuvonralimab) • BGB-108